← Back
NeuroTrials.ai
Neurology Clinical Trial Database

SPAN (Tocilizumab)

Evaluating Tocilizumab in Ischemic Stroke: Findings from the SPAN Multicenter Trial

Share Share Copied! Compare

Year of Publication: 2025

Authors: Anjali Chauhan, Eunyoung Angela Lee, Rakesh B. Patel, ..., Jaroslaw Aronowski

Journal: Neuropharmacology

Citation: https://doi.org/10.1016/j.neuropharm.2025.110801

Link: https://doi.org/10.1016/j.neuropharm.2025.110801

Clinical Question

Does tocilizumab (IL-6 receptor blockade) improve sensorimotor recovery and reduce brain tissue loss in preclinical rodent stroke models across different age groups, sexes, and comorbidity profiles?

Bottom Line

Tocilizumab did not provide overall benefit in the mouse cohort but showed modest motor improvements in aging mice and significant sensorimotor gains in hypertensive rats (particularly males), with early cerebroprotection that did not translate into durable tissue preservation. These findings support IL-6 signaling as a viable therapeutic target warranting further translational investigation.

Major Points

  • SPAN is a multicenter, randomized, blinded, placebo-controlled preclinical trial platform evaluating neuroprotective agents in rodent stroke models.
  • 701 rodents (1:1 male:female) were studied across four models: healthy young mice, diet-induced obese mice, aging mice, and spontaneously hypertensive rats (SHRs).
  • TCZ did not significantly improve long-term sensorimotor recovery or reduce brain tissue loss in the overall mouse cohort.
  • Aging mice showed modest motor function improvements with TCZ.
  • SHRs treated with TCZ demonstrated improved corner test scores on days 7 and 28 post-MCAO, particularly in males.
  • TCZ provided early cerebroprotection in SHRs with reduced lesion volume at day 2, but did not reduce tissue atrophy at day 30.
  • TCZ had previously fallen below the futility boundary after SPAN Stage 3, but the authors noted this may reflect both biological and design-related factors.
  • IL-6 trans-signaling amplifies pro-inflammatory effects in stroke; TCZ blocks both classical and trans-signaling pathways via IL-6R inhibition.
  • TCZ has shown cardioprotective effects in STEMI and post-cardiac arrest patients, supporting the rationale for stroke application.
  • These findings support further investigation of IL-6R inhibition as a potential stroke recovery therapy.

Design

Study Type: Multicenter, randomized, blinded, placebo-controlled preclinical trial (SPAN platform)

Randomization: 1

Blinding: Blinded (placebo-controlled with saline)

Follow-up Duration: 28–30 days post-MCAO

Countries: USA

Sample Size: 701

Analysis: Stratified analysis by age, sex, and comorbidities; behavioral and MRI morphometry endpoints

Inclusion Criteria

  • Healthy young mice
  • Diet-induced obese mice
  • Aging mice
  • Spontaneously hypertensive rats (SHRs)
  • Male and female rodents (1:1 ratio)

Arms

FieldTocilizumabControl
InterventionTocilizumab 100 mg/kg (mice) or 10 mg/kg (rats) after MCAOSaline placebo after MCAO
Duration

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Long-term sensorimotor recovery and brain tissue loss measured by behavioral testing and MRI morphometryPrimaryReference (saline)No significant overall improvement in mice; modest motor gains in aging mice; improved corner test scores in SHRs (days 7, 28)
Lesion volume at day 2 (SHRs)SecondaryReferenceReduced lesion volume (early cerebroprotection)
Tissue atrophy at day 30 (SHRs)SecondaryReferenceNo significant difference
Corner test scores in SHRs (male subgroup)SecondaryReferenceImproved at days 7 and 28, particularly in males

Subgroup Analysis

Aging mice showed modest motor function improvements. SHRs showed the most notable benefits, with improved sensorimotor function particularly in male rats. Diet-induced obese mice and healthy young mice did not show significant benefit. TCZ previously fell below futility boundary after SPAN Stage 3, but subgroup-specific effects were identified in this stratified reanalysis.

Criticisms

  • Preclinical study in rodents; results may not directly translate to human stroke patients.
  • TCZ fell below the futility boundary in the original SPAN analysis after Stage 3.
  • No durable tissue preservation despite functional improvements in some subgroups.
  • Humanized monoclonal antibody may interact differently with rodent IL-6R compared to human IL-6R.
  • Limited detail on exact statistical comparisons and p-values in available text.
  • Dosing regimen differences between mice (100 mg/kg) and rats (10 mg/kg) complicate cross-species comparisons.

Based on: SPAN (Tocilizumab) (Neuropharmacology, 2025)

Authors: Anjali Chauhan, Eunyoung Angela Lee, Rakesh B. Patel, ..., Jaroslaw Aronowski

Citation: https://doi.org/10.1016/j.neuropharm.2025.110801

Content summarized and formatted by NeuroTrials.ai.